September 15, 2016
RegMed Investors’ closing bell analysis, volatility puts a hex on upside pricing
September 15, 2016
Higher open expected; RegMed Investors’ pre-open, volatility is episodic and to be sold into
September 14, 2016
Slightly higher open expected; RegMed Investors’ pre-open, how ‘bout them apples?
September 13, 2016
RegMed Investors’ closing bell analysis, it’s … b a c k …!
September 9, 2016
RegMed Investors’ closing bell analysis, sell off
September 9, 2016
Lower open expected; RegMed Investors’ pre-open, is current pricing sustainable?
September 8, 2016
RegMed Investors’ closing bell analysis, stocks grind higher
September 7, 2016
RegMed Investors’ closing bell analysis, how is certainty and doubt priced?
September 7, 2016
Fate Therapeutics (FATE) and Memorial Sloan Kettering Cancer Center launch Partnership
September 6, 2016
RegMed Investors’ closing bell analysis, coming back in more ways than one
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.